A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study (Q33389469)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study (English)

1 reference

Europe PubMed Central

26 July 2017

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Angeles Alvarez Secord

6

object named as

Angeles Alvarez Secord

1 reference

Europe PubMed Central

26 July 2017

author name string

Brigitte E Miller

1

1 reference

Europe PubMed Central

26 July 2017

John A Blessing

2

1 reference

Europe PubMed Central

26 July 2017

Frederick B Stehman

3

1 reference

Europe PubMed Central

26 July 2017

Mark S Shahin

4

1 reference

Europe PubMed Central

26 July 2017

S Diane Yamada

5

1 reference

Europe PubMed Central

26 July 2017

David P Warshal

7

1 reference

Europe PubMed Central

26 July 2017

Ovadia Abulafia

8

1 reference

Europe PubMed Central

26 July 2017

William E Richards

9

1 reference

Europe PubMed Central

26 July 2017

Linda Van Le

10

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

8 May 2010

1 reference

Europe PubMed Central

26 July 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

26 July 2017

118

1 reference

Europe PubMed Central

26 July 2017

2

1 reference

Europe PubMed Central

26 July 2017

139-144

1 reference

Europe PubMed Central

26 July 2017

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Cisplatin as second-line chemotherapy in the treatment of advanced or recurrent leiomyosarcoma of the uterus. A phase II trial of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Paclitaxel in the treatment of carcinosarcoma of the uterus: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Promising combination therapies with gemcitabine

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Docetaxel administered on a weekly basis for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Combination Treatment with Weekly Docetaxel and Gemcitabine for Advanced Non–Small-Cell Lung Cancer in Elderly Patients and Patients with Poor Performance Status: Results of a Minnie Pearl Cancer Research Network Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Optimal flexible designs in phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Evaluation of paclitaxel in previously treated leiomyosarcoma of the uterus: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.03.024

7 January 2021

Identifiers

10.1016/J.YGYNO.2010.03.024

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33389469&oldid=1577698890"